Abstract:Purpose: The present study aimed to explore the clinical characteristics of heparin-induced thrombocytopenia (HIT) after surgery for acute type A aortic dissection and perform a relevant prognostic analysis. Methods: After continuous observation and analysis of 204 patients who underwent acute type A aortic dissection, we found that blood platelets decreased significantly after surgery and that these patients can be suspected to suffer HIT based on relevant 4Ts scores. For these suspected HIT patients, a latex particle-enhanced immunoturbidimetric assay was conducted to detect heparin-induced antibodies. Perioperative clinical data of patients in HIT and non-HIT groups were recorded as were blood platelet counts, HIT antibody test results, 4Ts scores, thromboembolic complications, clinical prognosis and outcomes. Results: In the present study, 38 suspected HIT patients, 16 HIT patients and 188 non-HIT patients were selected in the clinical setting. Among them, HIT patients were found to have prolonged cardiopulmonary bypass time (223 min on average vs. 164 min) and delayed aortic cross-clamp time (128 min on average vs. 107 min), and these differences between HIT patients and non-HIT patients were significant (P < 0.05). Additionally, the HIT group required longer operation time and higher dose of heparin, but showing no statistical differences (P > 0.05). The transfusions of blood platelets in the HIT group and non-HIT group were 18.7 ± 5.0u and 15.6 ± 7.34 u, respectively. In the HIT group, the mechanic ventilation time and the length of ICU stay were longer comparing the non-HIT group(P < 0.05), though no significant differences in total length of stay or In-hospital mortality were observed (P > 0.05). The incidence of continuous renal replacement therapy in HIT group was higher than the non-HIT group (P < 0.05). Additionally,there were no significant differences in 24-h postoperative drainage or reoperation for bleeding in both group(P > 0.05). However, the HIT antibody titer in the HIT group was significantly higher than that in the Suspected HIT group (2.7 ± 0.8 U/mL vs. 0.3 ± 0.2 U/mL) (P < 0.05). Among patients diagnosed with HIT, the incidence of thromboembolism reached 31.5%.For example, two HIT patients newly developed thromboembolism in both lower extremities,and three patients experienced cerebral infarction. Conclusions: After surgery for acute type A aortic dissection, HIT patients developed postoperative complications, the duration of ventilatory support and length of ICU stay were extended, and the incidence of thromboembolism increased. HIT antibody detection and risk classification should be implemented for high-risk patients showing early clinical characteristics.

[Clinical observation of heparin-induced thrombocytopenia].

Dabigatran Use after Argatroban for Heparin-induced Thrombocytopenia with Thrombosis: A Case Series and Literature Review

Heparin-induced thrombocytopenia: pathophysiology, diagnosis and treatment

Management of Heparin-Induced Thrombocytopenia: A Contemporary Review

EFFECT OF HEPARIN ON ACTIVATION OF PLATELET FUNCTION IN PATIENTS DURING RADIOFREQUENCY CATHETER ABLATION

Rivaroxaban in the treatment of heparin-induced thrombocytopenia: a report of 12 cases

Heparin-induced thrombocytopenia treated with fondaparinux: single center experience

Cerebral Venous Sinus Thrombosis Due to Low-molecular-weight Heparin-induced Thrombocytopenia

High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review

Rare Heparin Induced Thrombocytopenia Type I Reaction in a Hemodialysis Patient: Case Report.

Research on clinical characteristics and prognostic analysis of heparin-induced thrombocytopenia after surgery for acute type a aortic dissection

Comparative effectiveness and safety of anticoagulants for the treatment of heparin‐induced thrombocytopenia

Analysis of risk factors of heparin-induced thrombocytopenia

Heparin-Induced Thrombocytopenia in Patients Suffering Cardiogenic Shock

How to Solve the Conundrum of Heparin-Induced Thrombocytopenia during Cardiopulmonary Bypass

Evaluating heparin-induced thrombocytopenia: the old and the new

Absolute Immature Platelet Counts in the Setting of Suspected Heparin-Induced Thrombocytopenia May Predict Anti-Pf4-heparin Immunoassay Testing Results

Heparin-induced thrombocytopenia is associated with a high risk of mortality in critical COVID-19 patients receiving heparin-involved treatment

Heparin-Induced Thrombocytopenia in Patients Undergoing Venoarterial Extracorporeal Membrane Oxygenation

Heparin-Induced Thrombocytopenia is a High Risk of Mortality in Critical COVID-19 Patients Receiving Heparin-Involved Treatment

Results of an international survey of opinions on the definitions and treatments for heparin-induced thrombocytopenia: communication from the ISTH SSC Subcommittee on Platelet Immunology